Suggested remit - To appraise the clinical and cost effectiveness of nintedanib within its marketing authorisation for treating progressive fibrosing interstitial lung disease (PF-ILD).
In the light of COVID-19 NICE has prioritised our work programme. This topic has not been defined as therapeutically critical and has not been prioritised. We intended to begin this appraisal in April, invite the company and other consultees to make a submission, continue through to the delivery of the ERG report and then pause the appraisal. The company has asked NICE to delay this invitation by six months and we have agreed. This appraisal will therefore not start in April/May.
 
Status Suspended
Process STA 2018
ID number 1599

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
07 May 2020 Suspended. In the light of COVID-19 NICE has prioritised our work programme. This topic has not been defined as therapeutically critical and has not been prioritised. We intended to begin this appraisal in April, invite the company and other consultees to make a submission, continue through to the delivery of the ERG report and then pause the appraisal. The company has asked NICE to delay this invitation by six months and we have agreed. This appraisal will therefore not start in April/May.
06 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
08 November 2019 (14:00) Scoping workshop (Manchester)
23 September 2019 - 21 October 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
27 August 2019 The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of nintedanib for treating progressive fibrosing interstitial lung disease ID1599. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed appraisal. On receiving information from the company that markets nintedanib, NICE has agreed that holding a scoping exercise at this time is not appropriate. Consequently, the scoping workshop arranged for the 13 September 2019 will be cancelled. We apologise for any inconvenience this may cause. The Scoping workshop will be rescheduled to November 2019. If you have any comments or concerns, please contact the project manager for this proposed appraisal Michelle Adhemar via email on michelle.adhemar@nice.org.uk

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance